Compare Blackstone Inc (BX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Blackstone Inc. (BX) trades at $137.13, up 2.76% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41 billion in 2025, with a net income margin of 25.85%, while analyst consensus is a Buy with a $144.00 price target. Recent news includes a $16 billion Kuwait oil pipeline deal and the acquisition of a $25.3 billion Australian loan portfolio from HSBC, highlighting strategic expansion.

The outlook for BX is positive, driven by robust earnings growth and strategic acquisitions, but risks include market volatility and sector-specific pressures. Upside potential exists toward the consensus target, though overbought RSI levels near-term may prompt consolidation.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.